Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A star was rising fast, with the late Dr Phil Thorpe making the discoveries surrounding the IP assets, first thinking it had to be Targeting the blood vessels and in wonder exactly how the full MOA acted upon the cancers he seen being completely eradicated.
It turns out it was too much for Big Pharma to handle ....the cartel days were beginning to be realized, would be over....IF PS Targeting was allowed to flourish and something had to be done till it could be controlled and managed for combo IO
So we will skip all the sabotages and pay offs...to our latest, plan...to shift the IP assets.
From the prior post:
All those trials with Merck and Bavituximab ...nice
Thanks for the reminder Jake and I wonder how Mr Weissman would do in a deposition to go on the record with Peregrine Pharmaceuticals talks with Merck...looks like Merck never really could handle not being able to deal with Steve King and they had other plans to wait for the IP assets and Biomarkers
___
Stephen Weissman
Merck & Co., Inc. in its oncology collaboration with AstraZeneca, and its acquisitions of Peloton Therapeutics and Immune Design Corp.
Merck & Co., Inc. in various acquisitions and potential acquisitions, in the company's defense of competition law claims in various jurisdictions
https://www.bakerbotts.com/people/w/weissman-stephen?tab=experience
Thanks golfho and maybe one day ..we hear more
____
Andrew F Dorr -
April 21, 2017
F. Andrew Dorr, M.D., the Company’s previous interim chief medical officer, will transition his work to focus on the clinical development of the Company’s oncology programs.
https://seekingalpha.com/filing/3510273
______
Andrew F Dorr, who was not on research published reports of Peregrine re: biomarkers ...but does show up with Joe Shan, Steve King and Nikoletta Kallinteris with patent date filing below...dated
(Page 8 of 12 ...verified that MOS not met yet )
(54) METHODS FOR TREATING CANCER USING PS-TARGETING ANTIBODIES WITH IMMUNO -ONCOLOGY AGENTS
(71) Aplicant:
ONCOLOGIE,INC.,
WestNewton, MA (US)
(72) Inventors:
JosephS.Shan,Tustin,CA(US); NikoletaL.Kalinteris,Tustin,CA(US);
Min Tang,Tustin,CA (US);
F. Andrew Dorr,Tustin,CA (US)
(21) Apl.No.:15/943,304
(2)Filed: Apr.2,2018
https://patentimages.storage.googleapis.com/b4/e9/50/d138e8f8a7a2b2/US20180289771A1.pdf
________
Who knows, maybe S-Bio wants IP asset knowledge
S*BIO Pte Ltd
S*BIO Pte Ltd., a biotech company, focuses on the discovery, research, and clinical development of small molecule drugs.
Singapore, Central Region, Singapore
Categories
Biotechnology, Genetics, Life Science
Headquarters Regions
Asia-Pacific (APAC), Association of Southeast Asian Nations (ASEAN), Southeast Asia
Sub-Organization of
Logo of Chiron Corporation
Chiron Corporation
Founded Date
2000
Operating Status
Active
IPO Status
Private
S*Bio Pte Ltd. (Singapore), The principle activity of the company is the discovery and development of novel, proprietary small molecule anti-cancer drugs. This is done through an in-house discovery team located in Singapore and a clinical development team located in Singapore and Calfornia.
https://www.crunchbase.com/organization/s-bio-pte-ltd
_____
I wonder why Lana Gladstein was hired by Mark Bamforth new CDMO Arranta...maybe she advised Jeffrey Gladstein ( Merrill Lynch Wells Fargo) to buy big CDMO and maybe Christopher Sargent also of Merrill Lynch Wells Fargo buys big CDMO (Chris had to leave Wells Fargo for a reason and split off ....and started the buying already for some
As for Andrew F Dorr....he holds key Biomarker info and knows PS Targeting is huge ..so I wonder why James Allison and crew over at "Imaginab" required PS Targeting input from Andrew F Dorr ...as they seeked him out AFTER the patent and Biomarkers etc
Merck or another....should just open the vault
How many conflicts of interest exist with all Avid CDMO BODs ?
It seems they are afraid to speak ...yet Catherine Mackey not afraid to speak with PS Targeting patent filer Daniel Getts ...where she is Chair of BOD at Cour Pharmaceuticals
Has anyone received a response from Oncologie Inc or Avid CDMO BOD regards to other BPs and a simple MOA test to verify what other patents out there require PS Targeting knowledge etc and some that flat out targets nanoparticles that had flipped PS ?
Maybe the DOJ needs to be brought to Australia where they can be shown a live image feed on how cells act when flipped PS is targeted first
Anyone can file a damn patent on the Targeting of a protein after it originally targets flipped PS ....and some could not have known some protein pathways to even go after ....without those collaborations with Peregrine Pharmaceuticals that were never made public by Steven King ex CEO
I guess John Stafford had a job to do
Daniel Getts with Cour Pharma...who is with Catherine Mackey
_____
Patents by Inventor Daniel R. Getts
Daniel R. Getts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Modified immune-modulating particles
Patent number: 10471093
Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.
Type: Grant
Filed: February 17, 2015
Date of Patent: November 12, 2019
Assignee: Cour Pharmaceuticals Development Company.
Inventors: Daniel R. Getts, Rachael Terry, Nicholas King
_____
Meghann Teague Getts's research
while affiliated with Northwestern University and other places
Affiliations
Northwestern University
Department
Department of Microbiology-Immunology
The University of Sydney
Department
Discipline of Pathology
University of Zurich
Department
Institut für Experimentelle Immunologie
Top co-authors (50)
Daniel R Getts
Northwestern University
Nicholas Jonathan Cole King
The University of Sydney
Stephen D Miller
Northwestern University
Rachael L Terry
Children's Cancer Institute Australia
Iain L Campbell
The University of Sydney
Betabody patent to Oncologie .. where Avid CDMO has royalties milestones rights etc
Who is paying off Oncologie Inc that they can't even keep up to date on Betabodies records updating with the US patent office
All others should be demanding info out of Avid CDMO to ask who monitors any actions with Oncologie as they signed an agreement to advance the IP, not stall on it
___
BETABODY patent
Oct 14, 2019
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
https://trademarks.justia.com/862/48/betabody-86248425.html
Thanks 4our and it sure sounds like stock manipulation has been going on for a while and for just a CDMO ? : )
I would say the IP assets are worth more than some would like all to know
FINRA fraud investigators have been investigating Ronin Capital it seems as Chris Boden was poached by John Stafford there so I wonder when the Merck ties will go public
Jennifer Zachary at Merck and she came from Covington & Burling as Partner
We shall see if the DOJ finally gets the clearance to make a stance here with IP assets surrounding PS Targeting has been targeted and shorted and sabotaged multi times
I don't like Covington Burling because it seems that is where some ex DOJ try to flee like Lanny Breuer and Eric Holder and Steve Fagell ....as some of them may not press forward on Investigations at the DOJ as they should have and why is the question
So now we have DOJ Christopher M O'Connell and maybe he will go after the fraud "tied" to IP assets being held back ....I am sure he can call Jessica Zachary now at Merck ! and also ex Covington Burling
Damn... this sabotage of Peregrine Pharmaceuticals now Avid Bioservices CDMO is can be explained clearly so any trial lawyer can make any juror understand
Hopefully Covington Burling had some form of ethics that even Thomas O'Connell must know with NJ Supreme Court of attorney ethics ...and Jessica Parsons O'Connell at Covington Burling knows as well
Merck can't pay off everyone and many at the DOJ and FBI must see this clear line right over to John Springs Stafford
As for the Avid BOD ...like Catherine Mackey ...the newcomer ...she must know how valuable the IP assets are as she sits on the BOD and milestones / royalties etc payments look like they were held up ...but maybe as Chair of BOD at Cour Pharma...she likely had Daniel Richard Getts or Meghann Teague / Getts at Cooley LLP !! Telling her that she should just be quiet ....
The Cooley LLP connection to Meghann Teague ...now full circle right back to Avid BOD member(s) and the Ampersand crew ...too busy with other CDMOs
How can all simply be quiet? Paid off? Like Jeanette Bleecker possibly
More to come .... so let's see what Avid BOD members bring to the table
How many executive orders have Trump signed since he has been in office, signed to bring the best medical care for such a wide variety of diseases / cancers etc etc and this includes manufacturing
The IP assets from Peregrine which includes ...variances of Targeting etc and has Alex Azar aligned himself with the right parties to bring the best medical treatment forward and manufacturing
I guess Alex Azar ex Eli Lilly has decisions to make ...and will news break soon
Merck knows how Peregrine and the IP assets were always the target
Feng Xu knows exactly what I mean and very interesting ....Rich Richieri found out much about working with what protein pathways were important and all was kept under cover with Rubicon Biotechnology MRI Global etc etc ....so Avid has Rich Richieri back and Roche sidekick Arugadoss Devakumar all of a sudden scheduled for December 3 2019 meetings
Feng Xu .... how far is Merck willing to go ....everyone can't be paid off
All those involved with the Peregrine RNA seq library found out how valuable PS Targeting is...as it allowed for protein characterization to be fully characterized
Nice to see Stephanie answers so quickly...but maybe Stephanie is not aware of all thing that some don't know .... we shall see...
______
Avid Bioservices expands facility, process development capabilities
April 25, 2018
...
...
Avid said it has four new clients interested in accelerating development of their biologic-based candidates. Though the company did not identify the clients, it said it is helping them develop drug candidates "for application in certain cell therapy, respiratory and oncology indications."
"In just a few months, we have already matched the total new client wins for all of calendar 2017, and we are continuing to work to convert a strong pipeline of additional opportunities," said Avid CEO Roger Lias in a statement.
...
...
https://www.biopharmadive.com/news/avid-bioservices-expands-facility-process-development-capabilities/522170/
Maybe BDO can advise the IIS and market makers that their valuation of some IP assets / CDMO manufacturing etc and related M/A for life sciences are looking astronomically higher than expected
Patti Seymour will be with Avid Bioservices event Dec 3, 2019
Dec 3, 2019 from 10:00 AM to 2:00 PM EST
Technical Seminar
Speaker:
Patti Seymour Managing Director, BioProcess Technology Group - BDO USA, LLP
Dr. Hugh Davis Chief Business Officer - Frontage Laboratories, Inc.
Richard Richieri Chief Operations Officer - Avid Bioservices, Inc.
Dr. Arugadoss Devakumar Director, Analytical Development - Avid Bioservices, Inc.
Location:
Massachusetts Biotechnology Council
_____
TECHNOLOGY TRANSFER OF NOVEL IMMUNOTHERAPY PROGRAM: GVAX AND CRS-207
By: Patti Seymour
Presented at:
IBC’s BioPharmaceutical Development and Production Week; 2014 Mar 24-27; San Diego, CA.
Aduro BioTech is developing novel and complex immunotherapeutics for the treatment of oncology and infectious disease indications. This talk describes a case study for the selection of CMOs and technology transfer for Aduro’s lead clinical immunotherapy, which combines GVAX, a GM-CSF expressing tumor cell line and CRS-207, a live attenuated double deleted Listeria strain, in preparation for pivotal clinical trials. It covers the initial gap assessment process, CMO selection process and how the gap assessment was used to prioritize the technology transfer activities to ensure the knowledge and experience gained during development and early clinical manufacturing is effectively transferred. It concludes with lessons learned from the entire process.
https://www.bptc.com/technology-transfer-novel-immunotherapy-program-gvax-crs-207/
_______
Patti Seymour is back again, aligned with Avid Bioservices ...maybe those IIS will continue to find it a bit more difficult to collect CDMO shares
Who knows what we don't know....though BDO knows also how big PS Targeting is ...as it leads many to know the correct protein pathways to go after
Laura Hix Glickman - Nov 2012 to June 2017 Aduro
Bill Hanson - July 2009 to Dec 2018 Aduro
Chris Rae - July 2013 to Feb 2018 Aduro
Christopher Thanos - Sutro to Halozyme to Actym
________
BDO and you, stronger together.
BDO offers life science organizations a broad range of support, both for their current and potential government award portfolios in biodefense and pandemic response funded by:
Department of Health and Human Services (HHS)
Office of the Assistant Secretary for Preparedness and Response (ASPR)
Biomedical Advanced Research and Development Authority (BARDA)
Strategic National Stockpile (SNS)
National Institutes of Health (NIH)
Centers for Disease Control and Prevention (CDC)
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
Department of Homeland Security (DHS)
https://www.bdo.com/industries/life-sciences/bio-defense
______
BDO USA Acquires BioProcess Technology Consultants to Expand Product Development Advisory Services in Life Sciences
April 01, 2019 09:05 AM EST
https://www.businesswire.com/news/home/20190401005081/en/BDO-USA-Acquires-BioProcess-Technology-Consultants-Expand
_______
BDOs Merger, Growth into Biopharmaceuticals Explained
April 23, 2019 by INSIDE Public Accounting
In light of BDOs recent acquisition of BioProcess Technology Consultants (BPTC), INSIDE Public Accounting asked leaders from both firms to discuss further expansion within the life sciences industry, growth strategies and how the merger will help clients.
BPTC is a chemistry, manufacturing and controls consulting service. Chicago-based BDO (FY18 net revenue of $1.46 billion) sees the merger as expanding its existing services in developing new biopharmaceutical products while minimizing risk.
IPA spoke with Eric Jia-Sobota, national leader of BDOâ??s Industry Specialty Services and Life Sciences practices, and Howard Levine, Ph.D., managing director and national leader of the Bioprocess Technology Group within BDOs Life Sciences practice.
IPA: Its starting to become more common for accounting and advisory firms to acquire consulting firms, but often they are related to technology, such as cybersecurity. Acquiring a consultancy related to the biopharmaceutical industry is unusual. Why the interest?
Jia-Sobota: Our clients frequently look to leverage the industry experience and client-specific insights our collective team has, including in the life sciences realm. The life sciences industry is an important vertical for BDO especially as technologys infiltration of the space continues to create both new opportunities and mirroring risks.
For instance, while breakthroughs in CAR-T and other cell gene therapies have huge potential, biopharmaceutical manufacturers cant neglect investment in their manufacturing processes as demand for biopharmaceuticals continues to rise. While it may be tempting to invest in new facilities to alleviate production capacity shortages, in the long term, companies must invest in new technologies and methods for bioprocessing.
Biopharmaceutical manufacturers need to develop cost-effective methods for scaling their operations, or else lose a competitive edge to those whose investments in technology and new processes make their therapies more affordable. The addition of BPTC enhances our ability to help biopharmaceutical manufacturers meet these evolving demands and de-risk product development while at the same time capitalizing on new, tech-enabled opportunities to further improve patient outcomes.
IPA: What was so attractive about BioProcess Technology Consultants that made BDO pull the trigger on an acquisition?
Jia-Sobota: BDO and BPTCâ??s technical and operational services to life sciences entities are complementary, with a focus on helping organizations navigate risk, make informed investment decisions and seize new opportunities. The addition of BPTC supports the continued growth and diversification of life sciences capabilities at BDO.
IPA: How will this acquisition help BDO clients? Can you give me an example?
Levine: The addition of BPTC enhances BDOs ability to advise clients on technical, strategic and regulatory aspects of biopharmaceutical development at all stages in the product lifecycle. For instance, there is growing concern within the biopharma sector that current processes and facilities may not have capacity to meet rising global demand for high-volume biologics. Through the addition of BPTC, BDO can further assist companies in implementing process intensification practices that can help bridge the gap between supply and demand, while also improving process efficiency and even product quality.
IPA: BPTC founder Howard L. Levine is quoted as saying his firm helped companies address "unmet medical needs and increase patient access to novel medicines." How so?
Levine: While emerging technologies and innovations like CAR-T therapies and others show promise for treating formerly intractable diseases or injuries, rising costs limit their accessibility for patients. The professionals from BPTC who have joined BDO will complement our ability to help clients ensure the long-term success of therapies by helping them improve their cost-effectiveness while maintaining or improving efficacy. This may include developing and implementing process intensification strategies â?? such as continuous bioprocessing.
IPA: How does this acquisition fit into BDOs growth strategy?
Jia-Sobota: The addition of BPTC aligns with recent investments BDO has made in innovation across the firm â?? including added resources in technology solutions, digital transformation, risk advisory and data privacy. These additions position us well for continued growth in the coming years and align with our commitment to offering our clients a comprehensive suite of services across both industry agnostic and specific business imperatives.
IPA: What can clients expect in the future in terms of additional acquisitions like this one?
Jia-Sobota: As part of our commitment to client service, we are continuing to make investments in innovation that can bolster the support we provide clients across industries.
http://blog.insidepublicaccounting.com/2019/04/bdos-merger-growth-into-biopharmaceuticals-explained/
_________
Maybe...maybe we should ask George Addona Ass VP at Merck or better yet, Theresa Addona can just very the protein pathway changes that help ALL diseases via PS Targeting ...
Theresa still must be getting calls from some wondering about those proteins that fall in line "after" PS Targeting
PS Targeting is HUGE : ) and let's wait and see what Heather L. Wargo is stirring up
Cataract surgery will require PS Targeting combo drugs / as well as Intraocular surgery lens replacement - Avid CDMO BOD will be required to open all closed records of past before any sale
I agree and maybe Mackey can get the BOD moving ....I mean why wouldn't they tell that the top 10 BP just about takes up ALL capacity
If the CDMO market was not sizzling.. Ampersand would not be expanding CDMOs
650 Pleaseant St Watertown MA scheduled to be demolished and brand spanking new 35,000 sqft with Thermofisher partnering..(could be fraud with ThermoFisher....)
So we have Ampersand backed Arranta CDMO with more info leaking than Ampersand backed Avid CDMO? I guess they wouldn't be expanding a fleet of CDMOs with no assurances
Maybe Johnny Springs Stafford can have a sit down with Wendy Holman and Axel Hoos and they can advise Wayne Holman to advise Citadel to BUY BIG into Avid CDMO
Citadel and Ronin Capital...they seem to have a special bond
Very interesting and what percent of the float was traded on those big up days...in first few trading days of July? Maybe Wayne Holman will put in a offer for Avid Bioservices since it would help Ridgeback Capital and Ridgeback Biotherapeutics
Other than that not adding up (unless manipulation to simply buy cheap shares ) then we have Axel Hoos that is oh so happy that Dr Jedd Wolchok was stopped from having Bavi combo push GSK OX40 out of the picture
Axel a big GSK guy and pushing OX40 etc
___
What did Axel Hoos want? He did not seem to want Dr Jedd Wolchok to highlight Bavituximab combo better than OX40...as Dr Wolchok publicly put forth...
______
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Weiyi Peng,
Leila J. Williams,
Chunyu Xu,
Brenda Melendez,
Jodi A. McKenzie,
Yuan Chen,
Heather L. Jackson,
Kui S. Voo,
Rina M. Mbofung,
Sara Elizabeth Leahey,
Jian Wang,
Gregory Lizee,
Hussein A. Tawbi,
Michael A. Davies,
Axel Hoos,
James Smothers,
Roopa Srinivasan,
Elaine M. Paul,
Niranjan Yanamandra and
Patrick Hwu
DOI: 10.1158/1078-0432.CCR-19-1259
Published November 2019
Abstract
Purpose: OX40 agonist based combinations are emerging as a novel avenue to improve the effectiveness of cancer immunotherapy.
...
...
https://clincancerres.aacrjournals.org/content/25/21/6406
______
Next, we have Sabin Vaccine Institute help Holman ( after how much monies given? ) and the ties that will be coming are astronomical that will prove PS Targeting has always been the target ...
Remember, Wendy Commins Holman spouse is Wayne Holman ( SAC Steve Cohen tie) and Citadel has Brittany Commins and I wonder when John Springs Stafford comes clean and tells all what a mitake Ronin Capital made in painting a not so rosy picture for the IP assets help at Peregrine ...
___
https://www.sabin.org/updates/pressreleases/wendy-holman-joins-sabin-vaccine-institute-board-trustees
Wendy Holman Joins Sabin Vaccine Institute Board of Trustees
Wednesday, August 2, 2017
WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Wendy Commins Holman to its Board of Trustees. Ms. Holman is the CEO and founder of Ridgeback Biotherapeutics, a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases.
Prior to founding Ridgeback Biotherapeutics, Ms. Holman was a principal at Ziff Brothers Investments and director of research at ZBI Equities, a multi-billion dollar public equity investment fund where she spent 15 years guiding investments in healthcare and novel technology.
“We are very pleased to welcome Wendy to our board,” said Dr. Axel Hoos, chairman of Sabin’s Board of Trustees. “Her knowledge and experience of innovative technologies and deep interest in global health will be an important addition to the board as we advance our vision of a future free from vaccine-preventable diseases.”
The addition of Ms. Holman to the Board of Trustees comes as the Sabin Vaccine Institute has implemented a strategic plan and mission to make vaccines more accessible, enable innovation and expand immunization across the globe.
“I am delighted to join Sabin at such an opportune moment for the organization,” said Ms. Holman. “I look forward to supporting Sabin’s efforts to expand immunization and explore new scientific approaches to identify solutions with the potential to improve the lives of millions of people around the world.”
“It has been my privilege over the years to work with wonderful people and be able to assess and invest in health technology,” Ms. Holman said. “Now I am focused on bringing those solutions to everyone, regardless of where they were born. By championing immunization, we can have an immediate impact on human suffering. Every mother – every human being – should care about preventing disease and providing a healthy start for every child and every family.”
In addition to her role at Ridgeback Biotherapeutics, Ms. Holman serves as the campaign chair for the University of Pennsylvania’s new Biotech Commons and on the Penn Libraries Board of Overseers. She lives in Miami, FL with her husband and four children.
___
Cell surface receptors for phosphatidylserine contribute to the entry of Ebola virus (EBOV) particles, indicating that the presence of phosphatidylserine in the envelope of EBOV is important for the internalization of EBOV particles.
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006848
_____
Cohen has said in a deposition with the SEC that he decided to sell SAC Capital's position in Wyeth after speaking with Holman. Martoma's lawyers had sought to introduce the deposition at trial, but U.S. Judge Paul Gardephe denied the bid.
https://mobile.reuters.com/article/amp/idUSBREA0S04220140129
______
We recently demonstrated that a soluble protein, Gas6, can facilitate viral entry by bridging viral envelope phosphatidylserine to Axl, a receptor tyrosine kinase expressed on target cells. The interaction between phosphatidylserine, Gas6, and Axl was originally shown to be a molecular mechanism through which phagocytes recognize phosphatidylserine exposed on dead cells. Since our initial report, several groups have confirmed that Axl/Gas6, as well as other phosphatidylserine receptors, facilitate entry of dengue, West Nile, and Ebola viruses. Virus binding by viral envelope phosphatidylserine is now a viral entry mechanism generalized to many families of viruses. In addition to Axl/Gas6, various molecules are known to recognize phosphatidylserine; however, the effects of these molecules on virus binding and entry have not been comprehensively evaluated and compared. In this study, we examined most of the known human phosphatidylserine-recognizing molecules, including MFG-E8, TIM-1, -3, and -4, CD300a, BAI1, and stabilin-1 and -2, for their abilities to facilitate virus binding and infection. Using pseudotyped lentiviral vectors, we found that a soluble phosphatidylserine-binding protein, MFG-E8, enhances transduction. Cell surface receptors TIM-1 and -4 also enhance virus binding/transduction. The extent of enhancement by these molecules varies, depending on the type of pseudotyping envelope proteins. Mutated MFG-E8, which binds viral envelope phosphatidylserine without bridging virus to cells, but, surprisingly, not annexin V, which has been used to block phagocytosis of dead cells by concealing phosphatidylserine, efficiently blocks these phosphatidylserine-dependent viral entry mechanisms. These results provide insight into understanding the role of viral envelope phosphatidylserine in viral infection.
...
...
https://jvi.asm.org/content/jvi/88/8/4275.full.pdf
______
Ridgeback Biotherapeutics LP announces an update on mAb114, an experimental treatment for Ebola
....
To date, all funding for Ridgeback Biotherapeutics has originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place.
...
https://www.prnewswire.com/news-releases/ridgeback-biotherapeutics-lp-announces-an-update-on-mab114-an-experimental-treatment-for-ebola-300900098.html
____
PS regulates tumor immunity
Nov 20, 2019
https://investor.omeros.com/static-files/c0364b85-7862-4cfe-be63-d07508226ae4
Sept 10, 2019
https://investor.omeros.com/static-files/32f2f111-fc8f-47ec-b3ec-4a8a3ef931ac
https://investor.omeros.com/presentations
No complaint about Izzy yet..as if one looked at the shares being accumulated the first ...very first trading days of July ( qtr July Aug Sept ) which tell us that the slight increase in IIS should have been more ....so there remains a problem
Of course, anyone and everyone seen the EXACT shares swapped in and out of several hedge funds ....and all that "in combination" with Izzy ( Millennium Management ) jumping aboard tells a story
No worries ....puzzle pieces are surfacing all over and as for Merck Josh Harrell or other Nutters ....plenty of time to squeeze info
In the mean time .. Mark Bamforth knew of EXOSOMES Biomarkers and John Stafford was the lacky excuse for some to hide behind ...for now
Fortunately ...protein pathways and all relevant changes / Biomarkers will be proven by several third parties ...that will prove PS Targeting / data / email c etc are Min Tang worthy according to biostatistics
Mark Bamforth seems to not want Avid Bioservices BOD not listed on MassBio site, yet there is evidence of past "other" companies making their way through MassBio with PS Targeting patents / EXOSOMES etc
I wonder why Lana Gladstein was hired over to Arranta and a little conflict of interest with her and others ....knowing the IP assets at Avid Bioservices / future royalties and manufacturing rights are directly related ....maybe Jeffrey Gladstein tells her to just accept the monies and go along it ...as Merrill Lynch and others ...like Ronin Capital to Millennium Management etc etc....have much monies tied up on other plans
Very interesting links surfacing and more to be disclosed if Ampersand Capital can play it correctly
Maybe we can get some depositions from Josh Harrell ( ex Nutter McClennan Fish now works for Merck ) to clear things up or just bring in Israel Englander to give their side of the story
...What IP asset Biomarkers did Min Ting have knowledge of between Dana Farber and Peregrine Pharmaceuticals employment...must be worth Billions with that Biomarker knowledge ...as is Erez Eitan knowledge of PS Targeting that MassBio legal Nutter .. etc are well aware
______
Jeffrey Nathan Gladstein
AGE: 69
LOCATIONS
Narberth, PABala Cynwyd, PAPhiladelphia, PACharlotte, NCChambersburg, PANew York, NYArdmore, PA- less
RELATIVES
Lana Gladstein ( Mark Bamforth hired for Arranta )
Svetlana Gladstein
WORKED AT
Bank of America CorporationMerrill Lynch & Co. IncMerrill Lynch, Pierce, Fenner & Smith IncorporatedMerrill Lynch Capital Partners, Inc.Waterstone Capital Advisors, LLC- less
____________
In the meantime....still there are those Targeting flipped PS for CART / CTCs etc etc as Lockheed Martin posts recently along with Oded Biran
FILTRATION OF CIRCULATING TUMOR CELLS FOR THERAPUTIC PURPOSES
Publication number: 20170080142
Abstract: The present invention provides a method for filtration of CTCs directly out of patient blood and returning the blood after filtration to the patient. CTCs are an important factor for diagnosis and prognosis of cancer patients and can cause cancer metastasis. By eliminating CTCs from the bloodstream the chances for metastasis reduction decrease.
Type: Application
Filed: September 23, 2015
Publication date: March 23, 2017
Inventor: Oded Biran
https://patents.justia.com/patent/20170080142
__________
MassBio bio for Mark Bamforth
Mark R. Bamforth
President & CEO, Arranta Bio
About Mark
Mark Bamforth founded a new CDMO, Arranta Bio, in May 2019.
Previously, Mark founded Brammer Bio in 2015, a best-in-class viral vector contract development and manufacturing organization (CDMO) supporting cell and gene therapies. Brammerâ??s team grew from 110 in 2016 with the addition of 100 from the acquisition of two Biogen commercial facilities, to over 600 at the time of its acquisition by Thermo Fisher Scientific in April 2019.
In 2010, Mark founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team of 160 from J&J with a commercial supply agreement. Gallus tripled through organic growth and merging with Laureate Biopharma. Gallus was sold to DPx Holdings B.V. in Sept. 2014.
Mark previously spent 22 years in the UK and USA running a global manufacturing operation and a pharmaceutical CMO business for Genzyme and served as a corporate officer for 9 years.
He began his career as a petroleum engineer exploring for North Sea oil with Britoil, then as a chemical engineer in the whisky industry with Whitbread.
Mark serves on the boards of Avid Bioservices, MassBio, Wentworth Institute of Technology, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.
https://www.kget.com/news/politics/us-failing-to-stop-china-from-stealing-research-report-says/amp/
__________________
MassBio Welcomes Four Life Sciences Startups to Participate in MassCONNECT® Fall Mentorship Cycle
10/17/2018 Announcements
Entrepreneurs developing innovative solutions for:
Improving lead selection and clinical trial design
Enabling gene therapy and advancing treatment of autoimmune disease
Treating serious inflammatory and neurological disorders
Developing blood-based diagnostic tests for various neurological conditions
October 17, 2018 (CAMBRIDGE, MA) MassBios MassCONNECT®, the only mentoring program in Massachusetts that is solely dedicated to serving the needs of early-stage entrepreneurs in the life sciences, yesterday kicked off its third and final cycle of 2018 with a technology showcase. During the event, the four chosen life sciences startups presented their ideas to a room of industry executives and potential mentors for early feedback. Their research represents the incredible innovation spinning out of academia in Massachusetts, with this cycles cohort focused on improving lead selection and clinical trial design, enabling gene therapy and advancing treatment of autoimmune disease, treating serious inflammatory and neurological disorders, and developing blood-based diagnostic tests for various neurological conditions
This MassCONNECT cycle is being sponsored by Boehringer Ingelheim, Evaluate and Nutter.
"Boehringer Ingelheim is proud to be a continuing partner with the MassCONNECT program and mentor and support life science entrepreneurs in the thriving Massachusetts community," said Ioannis Sapountzis, Ph.D., Global Head of Business Development & Licensing for the USA & Specialty Care at Boehringer Ingelheim Pharmaceuticals, Inc. "As participants in the innovation ecosystem, we see this as a leading initiative to foster the best and brightest ideas and speed advancements to patients in need."
"The MassCONNECT mentoring program reflects both the entrepreneurial spirit and established expertise of the Massachusetts life science hub. Weâ??re delighted support this next generation of leaders with commercial insights that can help them bring new innovations to the industry," said Alex Karle, CEO, Evaluate Ltd.
"Nutter is excited to partner with MassCONNECT for the third time, as the participants demonstrate the cutting-edge technical expertise and incredible talent in Bostons life sciences and innovation communities," said Kathy Williams, Ph.D., a partner in Nutters Intellectual Property Department and co-chair of the firms Life Sciences practice group. "We look forward to mentoring and working with these pioneers in the health care industry."
Following this weeks showcase, entrepreneurs will be paired with a team of mentors, based on their individual objectives and needs, for eight weeks of hands-on coaching as they seek to develop business plans, launch companies and raise capital. The startups will then present in front of potential investors and partners.
The applicants chosen for the latest round of mentorship are:
-------
Javelin Biotech
Co-founders:
Murat Cirit, PhD;
Kevin O'Handley, MBA;
Emily Geishecker, MS
Javelin Biotech provides an integrative preclinical drug testing platform for the pharmaceutical and biotech industries by merging organ-on-chip (OoC) technologies and computational biology/AI to optimize lead selection and clinical trial design. Human OoC technologies culture human tissues in microphysiological environments enabling the most human relevant in vitro drug tests. The preclinical safety, efficacy, and pharmacokinetics data are translated to predictions of how drugs perform in humans without the gaps and shortcomings of animal models and other current approaches. Javelin Bio is interacting with FDA towards reducing animal studies for drug development and safety regulatory filings, helping to define the path towards using OoC tech and computations in place of animal tests.
--------
JURA Bio
Co-founders:
Julie Norville, PhD;
Elizabeth Wood, PhD;
George Church, PhD
Delivering on the promise of synthetic biology, JURA Bio is combining the newest advances in gene editing and therapeutic cell delivery to enable gene therapy and advance the treatment of autoimmune disease. Supported by world-leading clinical teams, the JURA Bio platform promises to meet the challenge of known and emerging autoimmune disorders with transformational therapies that promise to be both curative and definitive. JURA Bio, Inc. is actively developing its leading drug candidate, a novel class of CAR-T therapies against primary progressive multiple sclerosis (PPMS) and systemic lupus erythematosus (SLE). These leading therapies are the product of cell engineering, synthetic biology and clinical insight necessary to create a platform that may enable curative CAR-Ts in the fight against autoimmunity.
-------
NeuroCycle Therapeutics
Co-founders:
Jed Hubbs, PhD;
Matthew Toczko, PhD
NeuroCycle Therapeutics (NCT) discovers and develops therapeutics that act within the central nervous system to treat serious inflammatory and neurological disorders. Our science is based on cutting-edge research on the GABAA receptor and the latest disease-relevant in vivo pharmacology models. NCT will initially develop their lead candidate NCT10004 for moderate to severe atopic dermatitis. In addition, NCT is developing novel mechanisms for treating fibromyalgia, a chronic condition causing widespread muscle pain and fatigue; and Dravet syndrome, a rare and potentially fatal lifelong form of epilepsy that begins in infancy.
----
NeuroDex
Co-founders:
Erez Eitan PhD, MBA,
Oded Biran L.L.B, and
Raphael Nir PhD
NeuroDex Inc. is a diagnostics development company focusing on developing blood-based diagnostic tests for various neurological conditions. NeuroDexâ??s technology is based on the isolation of brain derived exosomes, nanoparticles which are regularly released into the bloodstream by brain cells. These exosomes can provide a window into the biology of the human brain. Their lead blood test can potentially diagnose Alzheimerâ??s Disease before the appearance of symptoms.
"We welcome this remarkable group of entrepreneurs into Cycle III and look forward to helping them shape and catalyze their inspiring ideas," said John Hallinan, Chief Business Officer at MassBio. "We want to recognize the MassCONNECT mentors for offering the immeasurable value of their experience and insights, and our ardent appreciation to Boehringer Ingelheim, Evaluate, and Nutter for their generous sponsorship."
About MassCONNECT
MassBios MassCONNECT program is the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences. MassCONNECT matches entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation. The MassCONNECT process involves a two-month mentorship where industry experts guide entrepreneurs as they seek to develop business plans, launch companies, and raise capital. MassCONNECT mentors evaluate and provide feedback on commercial feasibility; identify strengths, weaknesses, opportunities and threats; and team up to furnish industry-specific business advice for innovative ideas in therapeutics, diagnostics, medical devices and health IT. Entrepreneurs gain invaluable advice and coaching on defining value proposition, developing pitches and building professional networks. For more information, or to apply to be a mentor, mentee or MBA project manager, visit https://www.massbio.org/discover/massconnect.
https://www.massbio.org/news/recent-news/massbio-welcomes-four-life-sciences-startups-to-participate-in-massconnect-fall-mentorship-cycle-146533
______________
Cheynew, I agree Brian Sheehy and IsZo holding Avid Bioservices CDMO should make all question EVERY piece of the puzzle
We now know hedgde fund manipulations exist with exact stock trade swaps and we're they moved due to the investigations of certain parties
It is why I say all must continue to report all events to FBI FDA DOJ SEC as active investigations continue and maybe there is a portnoy of problems that can be discovered ....especially now since Israel Englander Millennium Management just so happened to increase their holdings this quarter
David Nickle goes from Merck to Gossamer and there seems to be clear evidence of fraud ...building
Had anyone heard anything about Axovant lately...remember, ex Roger Lias announced Avid CDMO ties to that ...vant company
Avid Bioservices CDMO in demand by Millennium and others, as Ronin Capital John Stafford simply is ignorant on how far things will go
There is a clear and evident, troubling situation arising right now...more than most all are aware ...and with Millennium Management tipping its hand in combination with EXACT trade swaps by hedge funds ...ALL must resend in all complaints to SEC FBI DOJ FDA because now, there is a trend of troubles that started with Ronin Capital up till now ...
More Millennium Management past troubles and are fines worth it? Millennium thinks so....so are Avid shareholders CDMO going to go quietly? or force those pulling some strings to be further investigated in ACTIVE investigations
Cheynew, thanks for the update and as expected...new IIS but more to come on all fronts
We have seen 100% that hedge funds and EXACT trade swapd have occurred and Millennium is not clean as Ronin Capital not clean
Hedge funds are OK with paying fines to get what they want....and Avid CDMO and PS Targeting is what many want ...so a little background on Millennium just as the past frauds of Ronin were exposed
Now, this should call to action for ALL Avid Bioservices CDMO shareholders to file complaints with SEC FBI DOJ FDA because one must refile all complaints prior sent in as there is an ACTIVE investigation
My dog can see the trading days of July and stock swaps this past quarter and all prior trading ....to see there is a problem
SEC can thoroughly comb thru ALL trades and all trades must be sought after again ....and then we will tie MORE puzzle pieces to come...
There are some NEW IIS with information on PS Targeting and Avid CDMO plans that some usually don't see till it is too late to buy in somewhat early
Too late in this may be, buying this in $5 range vs $20 range and many that do buy in $20 range will not settle for a $20 buyout depending upon Ampersand Capital plans
When other news flows, shareholders may demand 100% open access to all sealed court documents and all prior collaborations and ALL nondisclosure agreements signed
We may even have to see a surprise deposition from William Jay Treat or BARDA or Bone Biologics or many others ...
PS Targeting the Microsoft of Biotechnology as CP said ? Maybe that was on target
NASDAQ shows 44.07% (not including Dart and others )
Chicago ties Abbvie - Northern Trust added another 45,633 ...now owns over 600k shares
Royce & Associates add 34,000 now over 300k shares
A few NEW :
Prudential Financial 21,000
Winton Group 71,000
EAM Investments 111,000
....will be more and last quarter NASDAQ took a few extra days after the 15th before some showed up for public view
Nice, and AWM added over 100k shares also ...
(As of 6/30/2019) AWM investments only 11 new investments and Peregrine / Avid CDMO the #1 new investment with CBMG and Cryoport following
Top 3
Avid
CBMG
Cryoport
11 New Positions as of 06/30/2019
...
...
https://www.nasdaq.com/quotes/institutional-portfolio/awm-investment-company-inc-955123/new?sortname=companyname&sorttype=0
Cell banking and new borns having DNA cell banked big business now, as there is more puzzle pieces all resurfacing ....and PS Targeting is HUGE is what she said
______
Mr Baird COO of Arranta Bio...see PDF 6 below
https://www.watertown-ma.gov/DocumentCenter/Index/1756
There are questions why BOD at Avid working behind the scenes, very possibly diverting business over to Arranta or TriPharm or the other CDMOs Ampersand Capital is backing and many watching as Ampersand does not seem to be pulling full fiduciary duties for Avid CDMO
IIS increases again...now to 43.65% and with others from Ken Dart to others to strong hold retail we will be over 85% SOON
As we wait for the official confirmation for Avid CDMO BOD that expansion is required, Mr Baird will be at Watertown MA town hall meeting this evening re: 650 Pleasant St for new CDMO "Arranta" backed by Ampersand Capital and would Ampersand be backing all these NEW CDMOs with no forward guidance due to Avid Bioservices CDMO negotiations with ThermoFisher etc etc with Subcutaneous approvals around the corner ? What stops Bamforth from illegal activities to divert just a handful of clients to Arranta and leave Avid CDMO not needing expansion? ALL EYES are watching Mr Bamforth : ) ...from many directions and perfectly legal for the town to know ALL chemicals heading into such facilities
Omeros...PS Targeting en route and more to come, Targeting of PS requires no more Targeting of a dozen+ PS receptors and many questions directed to FDA and Federal Authorities
Don't put it past a backup plan for the Targeting of several receptors via Betabodies and remember, Betabodies Trademark etc NOT EXCLUSIVE to Bavituximab
Betabodies had been around 10+ years and NO PUBLIC research has been seen YET
Omeros 10k filed Nov 12, 2019 includes PS Targeting and compare this to ALL prior known MOA ( as we knew it then ) of PS Targeting and below is 100% PS Targeting
Ex Peregrine CEO Steve King had a PS Targeting PLATFORM and PROGRAMS as well ....where those collaborations were never disclosed ...hmmm
_______
Page 23
GPCR Platform and Programs. We have developed a proprietary cellular redistribution assay which we use in a high- throughput manner to identify synthetic ligands, including antagonists, agonists and inverse agonists, that bind to and affect the function of orphan GPCRs. We are conducting in vitro and in vivo preclinical efficacy studies and optimizing compounds for a number of targets. One of our priorities in this program is GPR174. In ex vivo human studies, our small-molecule inhibitors targeting GPR174 upregulate the production of cytokines (e.g., IL-2, interferon-?), block multiple checkpoints (e.g., PDL-1, CTLA-4, LAG-3) and tumor promoters (e.g., amphiregulin), and suppress regulatory T-cells. Based on our data, we believe that GPR174 controls a major pathway in cancer and modulation of the receptor could provide a seminal advance in immuno-oncologic treatments for a wide range of tumors. Our recent discoveries suggest a new approach to cancer immunotherapy that targets inhibition of GPR174 and can be combined with and significantly improve the tumor-killing effects of adenosine pathway inhibitors. These discoveries include (i) identification of cancer-immunity pathways controlled by GPR174, (ii) the identification of phosphatidylserine as a natural ligand for GPR174, (iii) a collection of novel small-molecule inhibitors of GPR174 and (iv) a synergistic enhancement of “tumor-fighting” cytokine production by T cells following the combined inhibition of both GPR174 and the adenosine pathway (e.g., A2A and/or A2B), another key metabolic pathway that regulates tumor immunity. We continue to focus on GPR174 and several other of our GPCR targets with the objective of moving compounds targeting them into human trials.
https://investor.omeros.com/static-files/f47dc3ec-d19f-4adf-8e65-f06c9627d91e
PS Targeting is HUGE w/MRI images and Biomarkers to back it up
Louis Gerstner ties to Memorial Sloan Kettering etc has daughter Elizabeth Gerstner that last updated in a more public release in Nov 2018 and I noticed NO stopping of that GMB trial with Bavituximab and I imagine some Biomarkers being cross analyzed with Alzheimer's MRI patient images are worth BILLIONS
Note: GMB here is Glio ...not to be confused with single atom thick Graphene...where GBM Graphene Based Materials in production as well for PS Targeting etc
_________
I guess some don't know what some don't know and those that hide PS Targeting fortunes will think twice to what one thinks one can get away with
_________
Neuro Oncol. 2018 Nov;
20(Suppl 6): vi191.
Published online 2018 Nov 5. doi: 10.1093/neuonc/noy148.792
PMCID: PMC6216505
NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE
Ina Ly,1
Jonathan Cardona,2
Andrew Beers,2
Ken Chang,2
James Brown,2
David Reardon,3
Isabel Arrillaga-Romany,4
Jorg Dietrich,1
Deborah Forst,1
Eudocia Lee,3
Justin Jordan,5
Lakshmi Nayak,3
Patrick Wen,6
Tracy Batchelor,4
Jayashree Kalpathy-Cramer,7 and
Elizabeth Gerstner1
1Massachusetts General Hospital, Boston, MA, USA 2Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, USA
3Dana-Farber Cancer Institute, Boston, MA, USA 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
5Massachusetts General Hospital, Department of Neurology, Boston, MA, USA
6Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
7Athinoula A. Martinos Center for Biomedical Imaging,
Boston, MA, USA
Abstract
BACKGROUND Glioblastoma and tumor endothelial cells express phosphatidylserine, a highly immunosuppressive membrane phospholipid. Bavituximab a chimeric monoclonal antibody binds to 2-glycoprotein 1 (2-GP1) to form a complex of 2-GP1 with phosphatidylserine, resulting in immune activation against tumor cells and anti-angiogenic effects. Phase I/II trials in other solid cancers have demonstrated response rates up to 85% when bavituximab was given with cytotoxic chemotherapy. Pre-clinical data in glioblastoma models suggested synergistic effects of phosphatidylserine blockade, radiation, and temozolomide (TMZ). METHODS In this ongoing phase II trial (NCT03139916), adult patients with IDH-wild-type newly diagnosed glioblastoma receive 6 weeks of chemoradiation, followed by 6 cycles of adjuvant TMZ (C1-C6 aTMZ). Bavituximab (3 mg/kg) is given weekly, starting week 1 of chemoradiation, for 18 weeks with the option to continue if tolerated. Physiologic MRIs are performed pre-treatment, pre-C1, pre-C3, and pre-C5 aTMZ. Within the enhancing tumor region, we measured median tumor Ktrans (reflecting vascular permeability) and relative cerebral blood volume (rCBV). Median percent changes during treatment were compared to pre-treatment values. RESULTS To date, 25 of 36 anticipated patients have enrolled (10 with MGMT promoter methylation). All patients underwent pre-treatment scans. 13 have evaluable pre-C1 and 8 pre-C3 aTMZ scans. On the pre-C1 MRIs, enhancing volume decreased by 39% and median tumor Ktrans and rCBV did not change significantly. On the pre-C3 MRIs, enhancing volume decreased by 11% and Ktrans and rCBV decreased by 17% and 21%, respectively. Five patients experienced radiographic disease progression after a median of 2.6 months and 1 patient died 76 days after diagnosis due to disease progression. Bavituximab was generally well tolerated.
CONCLUSIONS: Combining bavituximab with radiation and temozolomide results in decreased enhancing tumor volume, permeability, and cerebral perfusion. Continued patient accrual and imaging marker evaluation are underway to investigate the correlation be
True, many don't know what many don't know ...but we do know that a very, improbable, irregular list of events occurred, as some impossible list of events have amassed (taken as a whole...) from the beginnings of the late Dr Thorpe's work with the IP assets from Bavi to Betabodies and all in between.
Further, SEC trade filings from over the years will prove things that may not go public...right up to "EXACT" trades of transfer of shares that were pointed out last quarter ....again, impossible to have happened unless multiple hedge funds were working together
Now...taken all these events and bringing us to some midlife crisis that will fall upon some, because Apollo Group Management will be tied to some events as subsidiary MidCap Financial listed under IP assets...but if they listen to some here they should just give up those assets...eh? lol
MidCap Funding III ties to MidCap Financial and is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, LLC, pursuant to an investment management ...
____
Constructs binding to phosphatidylserine and their use in disease treatment
Abstract
Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.
Images (28)
Classifications
C07K14/775 Apolipopeptides
View 20 more classifications
US20060228299A1
United States
Download PDF Find Prior Art Similar
Inventor
Philip Thorpe
Troy Luster
Steven King
Current Assignee
MIDCAP FUNDING III LLC
Peregrine Pharmaceuticals Inc University of Texas System
Worldwide applications
2006 WO NZ DK AU ES SI EP US JP CN CA CN SG CN 2007 IL 2012 JP 2014 HK 2015 US HK 2016 US
Application US11/339,392 events
2005-01-24
Priority to US64633305P
2006-01-24
Application filed by Peregrine Pharmaceuticals Inc, University of Texas System
2006-10-12
Publication of US20060228299A1
2015-02-17
Publication of US8956616B2
2015-02-17
Application granted
2019-11-11
Application status is Active
2027-12-10
Adjusted expiration
______
I admit, information overload is what some will see at first sight....but others see a clear, very well designed plan...to hijack the IP and science behind Billions of $$$ of required patents many will require to pay licensing fees
______
Eli Lilly had most recently went public in ways....and is it a coincidence for them just hiring Brownstein Hyatt Farber Schrek just in last 24 hours? I noticed ex Merck now Brownstein "Jerome Murray landed at Brownstein as well just in Dec 17, 2018
____
Nov 11, 2019
Eli Lilly hires Brownstein Hyatt
By THEODORIC MEYER 11/11/2019 02:30 PM EST
Presented by REALTOR®
With David Beavers and Daniel Lippman
NEW BUSINESS: Eli Lilly has added Brownstein Hyatt Farber Schreck to its lineup of Washington lobbying firms. Zach Pfister, Marc Lampkin, Emily Felder, Nadeam Elshami and Brian Wildwill represent the pharmaceutical giant. Elshami is a former chief of staff to House Speaker Nancy Pelosi. Eli Lilly has spent nearly $5.1 million on Washington lobbying so far this year, according to disclosure filings, and also retains
https://www.politico.com/newsletters/politico-influence/2019/11/11/eli-lilly-hires-brownstein-hyatt-782212
____
Many don't know what many don't know
Min, I have posted more facts directly related to PS Targeting and I say * IP Assets * which INCLUDES Bavituximab ...though it does not end with Bavituximab
Within my past dozen posts I specifically already gave examples on how Bavi patents could be extended and when do those patents expire? I have posted that also
How about reminding folks PS Targeting will include dozens of targets, SURPRISING COMBINATIONS ...eh?
Betabodies, directly related to PS Trgeting .."as of now" expires Dec 10, 2027
If one comes thru my posts, you will realize that 2027 will be extended as well
The onion is being peeled back one later at a time....and I have hundreds of layers
___
Constructs binding to phosphatidylserine and their use in disease treatment
Abstract
Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases.
Images (28)
Classifications
C07K14/775 Apolipopeptides
View 20 more classifications
US20060228299A1
United States
Download PDF Find Prior Art Similar
Inventor
Philip Thorpe
Troy Luster
Steven King
Current Assignee
MIDCAP FUNDING III LLC
Peregrine Pharmaceuticals Inc
University of Texas System
Worldwide applications
2006 WO NZ DK AU ES SI EP US JP CN CA CN SG CN 2007 IL 2012 JP 2014 HK 2015 US HK 2016 US
Application US11/339,392 events
2005-01-24
Priority to US64633305P
2006-01-24
Application filed by Peregrine Pharmaceuticals Inc, University of Texas System
2006-10-12
Publication of US20060228299A1
2015-02-17
Publication of US8956616B2
2015-02-17
Application granted
2019-11-11
Application status is Active
2027-12-10
Adjusted expiration
_________
MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, LLC, pursuant to an investment management ...
John Springs Stafford in a bit of trouble it seems ....eh?
________
ECG, the IP assets and contracts are completed and IF the IP assets had no value...then Avid Bioservices CDMO would not have 15% about to net sales on any approvals and wouldn't have been guaranteed ALL manufacturing
I guess some like to still ...create fog ...as the IP is not only Bavituximab and not only Targeting of PS
The IP assets and patent expiration is simply a smoke and mirrors ...as I have already explained how extensions come into play
____
Gla domains as targeting agents
United States
The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.
The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.
Terry Hermiston
CEO at GLAdiator Bioscience
GLAdiator BiosciencesUniversity of Iowa
Richmond, California500+ connections
Experience
GLAdiator Biosciences
CEO
GLAdiator Biosciences
Aug 2018 – Present
1 year 4 months
....
Based on a 2 year collaboration between Bayer HealthCare and Stanford University, the company is centered on a unique biologics platform that targets and internalizes into cells expressing phosphatidylserine (PS) on their cell surface.
...
...
_____
Patents and extensions...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152151696
_______
If Dana Farber and Gordon Freeman thought like some here....his work would have never been recognized and the IP assets all held by Peregrine ....where Avid CDMO receives royalties 15% and manufacturing etc...is pending big right now
_______
Why do you think Omeros comes forward now to admit PS Targeting is REQUIRED?
https://www.marketwatch.com/press-release/omeros-discovers-new-cancer-immunity-pathways-controlled-by-gpr174-2019-09-10?mod=mw_quote_news
PS Targeting is HUGE
I guess we are all here for some reason and yes, this is the Avid Bioservices CDMO ihub board....and Avid made a contract with Oncologie and others etc for IP asset rights which were NEVER fully disclosed to all shareholders but we were told about milestones royalties etc and in 15% range for net sales
ALL involved with those contracts ..past and present are 100% direct related to this board
It is fact DARPA and MANY others have been involved and Merck and many others try oh so hard to contain the info
I will say, some here that can't see it or know it...have not followed all roads to PS Targeting because the amount of information, important information ...is information overload upon some that can't follow all paths
If one is an investor in CDMO and knows we have potential...astronomical potential..
One could ask Levi Garraway or Jennifer Wipf or others Ginkgo Bioworks or Bill Gates : )
PS Targeting is HUGE and it is FACT PS Targeting IP assets / Biomarker data etc with Ginkgo Bioworks affiliates and Lockheed Martin
Let me say this....ANYTHING from stressed cells to inflammation to cancer etc has flipped PS ....I posted an interview with Laura Benjamin CEO of Oncologie that also knows well
So any atom thick brain cell knows flipped PS must be targeted and to extract the impure substance from blood will require a license to Avid Bioservices CDMO
Information Overload is what new comers will see .....and by following all paths...then one will see my posts are 100% relevant to Avid Bioservices CDMO
Those cytokine storms are not welcome in any FDA future approval and maybe Bruce Artim now with Omeros...I mean now with Eli Lilly will tell you when he is allowed to. I work for no one and have signed no non disclosures unlike many others.
https://www.govinfo.gov/content/pkg/CRECB-2006-pt18/html/CRECB-2006-pt18-Pg23602-2.htm
_______
Patents by Inventor Svetlana Monakhova BACHMANN
Svetlana Monakhova BACHMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
GRAPHENE-BASED FILTER FOR ISOLATING A SUBSTANCE FROM BLOOD
Publication number: 20170128891
Abstract: A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle.
Type: Application
Filed: January 19, 2017
Publication date: May 11, 2017
Applicant: Lockheed Martin Corporation
Inventors: Svetlana Monakhova Bachmann, Paul Declan Mountcastle, Byron W. Tietjen
....
....
Graphene-based filter for isolating a substance from blood
Patent number: 9572918
Abstract: A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle.
Type: Grant
Filed: June 21, 2013
Date of Patent: February 21, 2017
Assignee: LOCKHEED MARTIN CORPORATION
Inventors: Svetlana Monakhova Bachmann, Paul Declan Mountcastle, Byron W. Tietjen
...
...
GRAPHENE-BASED FILTER FOR ISOLATING A SUBSTANCE FROM BLOOD
Publication number: 20140377738
Abstract: A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle.
Type: Application
Filed: June 21, 2013
Publication date: December 25, 2014
Inventors: Svetlana Monakhova BACHMANN, Paul Declan MOUNTCASTLE, Byron W. TIETJEN
_______
Lockheed Martin collaborates with Ginkgo Bioworks
_____
This maturation requires collaboration between ARL and Lockheed Martin and leverages commercial advances from companies such as Ginkgo Bioworks.
_____
https://www.prnewswire.com/news-releases/lockheed-martin-is-reprogramming-cells-to-bioproduce-new-materials-300802154.html
Lockheed Martin is Reprogramming Cells to Bioproduce New Materials
$10 Million Army Research Contract Advances Precision Biodesign
NEWS PROVIDED BY
Lockheed Martin
Feb 26, 2019, 11:04 ET
PALO ALTO, Calif., Feb. 26, 2019 /PRNewswire/ -- Cells form the cornerstone of life, and Lockheed Martin (NYSE: LMT) is researching ways to create the building blocks of novel materials. In a new cooperative agreement with the Army Research Laboratory, Lockheed Martin material scientists will work with industry and Army scientists who design microbes to edit single-cell organism DNA. They will investigate a range of capabilities, particularly those that can improve defense optical technology and coatings.
"Cells efficiently create all sorts of materials, like a spider's silk or a butterfly's iridescent wings. We want to harness nature's process to better protect people," said Melissa Rhoads, senior research manager and Lockheed Martin lead for the project. "Biodesign exists today, but it doesn't exist at the scale and to the quality of defense standards."
Biology and technology intersect in the field of biodesign. Some fashion houses even use the sustainable technology to develop fabrics for clothing, but Lockheed Martin sees potential to mature the science to a more precise level. This maturation requires collaboration between ARL and Lockheed Martin and leverages commercial advances from companies such as Ginkgo Bioworks.
Scientists often look to nature to provide inspiration, and those ideas can help lower the cost of optical technologies. For example, telescopes use lenses to filter out unwanted light or to get a clearer image. However, a squid lens is able to filter and focus light in compact package due to molecule-based design and varied refractive index. In another example, melanin protects humans and animals alike from the Sun's UV rays. So melaninâ??or similar molecules with protective functionsâ??could be another natural substance attracting the study's attention.
"We can't manufacture that kind of capability, so Lockheed Martin will try nature's way," Rhoads said. "Harnessing the power of self-assembling materials is sustainable, affordable and can be much faster to produce than artificial methods. As much potential there is for biodesign, the maturity of the materials technology is still low, so our five-year study will advance this field significantly for precision science."
The $10 million, five-year agreement uses the name Self-Assembly of Nanostructures for Tunable Materials and will leverage the Army's Open Campus model to enable collaboration between university, small-business, Army and Lockheed Martin scientists and engineers. Partnerships across industry and government groups have grown from programs like the National Science Foundation's SynBERC and the Department of Defense's Applied Research for Advancement of Science and Technology Priorities.
About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 105,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.
SOURCE Lockheed Martin
Related Links
http://www.lockheedmartin.com
PS Targeting is HUGE and Avid Bioservices CDMO has the deal mostly completed with about 15% royalties on net sales but there may be a surprise to come on those fronts...depends on what Oncologie does or refuses to do...
For now, Eli Lilly / Omeros now has some of the facts that will prove the protein pathways DEPEND upon PS Targeting ....
Elsid...now you may have your volume Spike and here is a bonus for the weekend as I would not have expected this news till next week
Further BONUS...There are others hopping on this PS Targeting trail and Oncologie? The hell with them if they can't get their heads out of the sand(box) and move this along NOW
There is a network of NEW IIS that don't want me saying much but now, we have another wave front that will push this to new levels that some Big Pharma will not like....the 9-11 first responders are all soon being connected to the info and Big Pharma types HIDING Lung Cancer new treatment that DEPENDS on PS Targeting and you think all the reporters will accept dying or money or nondisclosures?? NO WAY
Merck Keytruda was helped HUGELY by Bavituximab, a PS Targeting drug...with those approvals based on them Biomarkers...going to Avid Bioservices CDMO on about 15% royalties net sales
More to come...but the reporters and ALL that were down in Manhattan at the towers that witnessed the death tolls will not accept the death of PS Targeting by Big Pharma. Trust me...Big Pharma may have gotten their way for the past hundred years but times have changed and MANY have access to equipment that PROVES the MOA of many drugs...and why would the FDA refuse to verify special requests?? Ex Eli Lilly ...now head of Health and Human Services that is responsible for over $800M ++ in funds will also have decisions to make but know this...many will look Stafford foolish, knowing the facts are coming that prove PS Targeting gives all the most optimal immune response to have a fighting chance. The Enlightenment Age of Disease is what I have called it for years...
Since I work for no one ...and have not signed any non disclosure ...here you go
John Springs Stafford was hired by who?
Ampersand Capital was promised what?
The late Dr Phil Thorpe spent his life on helping Millions fight back disease to cancer and his PS Targeting patents will hopefully be known world wide ...soon and all those that ever signed a non disclosure to agree to stop fighting for the most optimal immune response may change their minds to speak now
_____
Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
1 hr ago
SEATTLE--(BUSINESS WIRE)--Nov 8, 2019--
Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled "Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses" at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.
Marc Gavin, Ph.D., Omeros Director of Immunology, will present the companys new findings that phosphatidylserine, a product of cell stress and death that is abundant in the tumor microenvironment (TME), directly stimulates GPR174 and attenuates T-cell responses.
Adenosine, another product of the TME, is well known to stimulate the same suppressive pathways through different GPCRs, and inhibition of both pathwaysâ??with adenosine receptor antagonists and with Omeros novel GPR174 inhibitors results in maximal enhancement of T-cell function, which should translate to effective resistance to the immunosuppressive nature of the TME.
The data will also feature new findings from animal tumor models, which validate GPR174 inhibition for cancer immunotherapy.
Designated B45, the poster will be presented in Poster Session B on Tuesday, November 19, 4:30 p.m. to 7:00 p.m.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.
https://www.valdostadailytimes.com/news/business/omeros-to-present-gpr-data-at-upcoming-american-association-for/article_c102be9f-2412-58a6-b096-08ae651835e5.html
Looks like you are not up to speed on Eli Lilly or Omeros or others monitoring live, protein pathways changes... while Targeting PS
The days of having a drug approved based on a tumor growth stopping are over and there are NEW IIS ..I mean new ways to monitor protein pathways and Merck must be a little upset that others have the info
Keytruda was helped HUGELY by Bavituximab ...just ask the FDA if they are allowed to tell ...yet
https://www.biospace.com/article/releases/omeros-discovers-new-cancer-immunity-pathways-controlled-by-gpr174/